BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23409032)

  • 1. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
    Gaujoux S; Hantel C; Launay P; Bonnet S; Perlemoine K; Lefèvre L; Guillaud-Bataille M; Beuschlein F; Tissier F; Bertherat J; Rizk-Rabin M; Ragazzon B
    PLoS One; 2013; 8(2):e55743. PubMed ID: 23409032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
    Salomon A; Keramidas M; Maisin C; Thomas M
    Oncotarget; 2015 May; 6(13):11421-33. PubMed ID: 25823656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
    Brown TC; Nicolson NG; Korah R; Carling T
    J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
    Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
    Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AXIN genetic analysis in adrenocortical carcinomas updated.
    Guimier A; Ragazzon B; Assié G; Tissier F; Dousset B; Bertherat J; Gaujoux S
    J Endocrinol Invest; 2013 Dec; 36(11):1000-3. PubMed ID: 23812285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors.
    Chapman A; Durand J; Ouadi L; Bourdeau I
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1477-81. PubMed ID: 21733995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
    Hui W; Liu S; Zheng J; Fang Z; Ding Q; Feng C
    Cancer Med; 2018 Apr; 7(4):1440-1449. PubMed ID: 29532999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
    Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
    Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer.
    Laha D; Grant RRC; Mishra P; Boufraqech M; Shen M; Zhang YQ; Hall MD; Quezado M; De Melo MS; Del Rivero J; Zeiger M; Nilubol N
    J Exp Clin Cancer Res; 2022 Sep; 41(1):282. PubMed ID: 36151566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
    Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis.
    Leal LF; Bueno AC; Gomes DC; Abduch R; de Castro M; Antonini SR
    Oncotarget; 2015 Dec; 6(40):43016-32. PubMed ID: 26515592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of MED27 inhibits adrenal cortical carcinogenesis by targeting the Wnt/β-catenin signaling pathway and the epithelial-mesenchymal transition process.
    He H; Dai J; Yang X; Wang X; Sun F; Zhu Y
    Biol Chem; 2018 May; 399(6):593-602. PubMed ID: 29730647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients.
    Abduch RH; Carolina Bueno A; Leal LF; Cavalcanti MM; Gomes DC; Brandalise SR; Masterallo MJ; Yunes JA; Martinelli CE; Tone LG; Tucci S; Molina CA; Ramalho FS; Moreira AC; Cardinalli IA; Scrideli CA; Ramalho LN; de Castro M; Antonini SR
    Oncotarget; 2016 Dec; 7(51):84634-84644. PubMed ID: 27705928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
    Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
    Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTNNB1 Knockdown Inhibits Cell Proliferation and Aldosterone Secretion Through Inhibiting Wnt/β-Catenin Signaling in H295R Cells.
    Zhou T; Luo P; Wang L; Yang S; Qin S; Wei Z; Liu J
    Technol Cancer Res Treat; 2020; 19():1533033820979685. PubMed ID: 33287648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells.
    Doghman M; Cazareth J; Lalli E
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3222-5. PubMed ID: 18544621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.
    Liu-Chittenden Y; Jain M; Gaskins K; Wang S; Merino MJ; Kotian S; Kumar Gara S; Davis S; Zhang L; Kebebew E
    Oncogene; 2017 Jun; 36(25):3541-3552. PubMed ID: 28114280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.